Vitamin D3 potentiates the growth inhibitory effects of metformin in DU145 human prostate cancer cells mediated by AMPK/mTOR signalling pathway. (June 2015)

• Record Type: Journal Article
• Authors: Li, Hong‐Xia; Gao, Jing‐Miao; Liang, Jia‐Qi; Xi, Jun‐Min; Fu, Meng; Wu, Yong‐Jie
• Is Part Of: Clinical and experimental pharmacology and physiology. Volume 42:Number 6(2015:Jun.)
• Page Start: 711
• Page End: 717
• Publication Date: 2015-06
• Subjects: Clinical pharmacology -- Periodicals; Pharmacology, Experimental -- Periodicals; Physiology, Experimental -- Periodicals; Physiology, Pathological -- Periodicals; 615.1
• DOI: 10.1111/1440-1681.12409
• Languages: English
• ISSNs: 0305-1870

Abstract

<abstract abstract-type="main" id="cep12409-abs-0001"> <title>Summary</title> <p>Metformin and vitamin D₃ both exhibit a strong antiproliferative action in numerous cancer cell lines, including in human prostate cancer cells. Here we showed that the combination of the two drugs had a much stronger effect on DU145 human prostate cancer cell growth than either drug alone. In this research, cell proliferation was measured by methylthiazol tetrazolium (MTT) assay. Cell apoptosis was determined with Hoechst 33342 staining. Western blotting and cell cycle analyses were used to elucidate potential mechanisms of interaction between the drugs. It is shown that in cultured DU145 cells, vitamin D₃ combined with metformin exhibits synergistic effects on cell proliferation and apoptosis. The underlying antitumor mechanisms may involve altered cycle distribution with a G1/S cell cycle arrest, activation of phospho‐AMPK with subsequent inhibition of downstream mTOR signalling pathway, down‐regulate c‐Myc expression, and reducing the level of anti‐apoptotic protein p‐Bcl‐2. In conclusion, metformin and vitamin D₃ synergistically inhibit DU145 cell growth, indicating a promising clinical therapeutic strategy for the treatment of androgen‐independent prostate cancer.</p> </abstract>